Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

BACKGROUND: Non–small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance invariably develops. Ceritinib (LDK378) is a new ALK inhibitor that has shown greater antitumor potency than crizotinib in pre...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Shaw, Alice T., Kim, Dong-Wan, Mehra, Ranee, Tan, Daniel S.W., Felip, Enriqueta, Chow, Laura Q.M., Camidge, D. Ross, Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin, Liu, Geoffrey, Santoro, Armando, Lau, Yvonne Y., Goldwasser, Meredith, Boral, Anthony L., Engelman, Jeffrey A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4079055/
https://ncbi.nlm.nih.gov/pubmed/24670165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1311107
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak